On the stock market since 2004, it operates in the world of health and science. It has 405 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $459.4M would still be left in the vault — a solid cushion for hard times.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
There is $713.8M in the vault; even if every debt were paid off, $459.4M would remain.
The average analyst price target is $27.00 — 74% above today’s price.
Over the last 3 years, sales fell about 14% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 67 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, DVAX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: DVAX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.